pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

6,918 products tracked · 6,918 matching

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
Marketed
binimetinib
Mektovi (binimetinib)
Metastatic Melanoma
Array BioPharma Inc
0 catalysts
pre_registration
binimetinib + encorafenib
Braftovi + Mektovi (binimetinib + encorafenib)
Metastatic Colorectal Cancer
$PFEPFIZER INC
0 catalysts
Phase 2
bintrafusp alfa
Bile Duct Cancer (Cholangiocarcinoma)
Programmed cell death 1 ligand 1Transforming growth factor beta
← prev
page 160 of 231
next →
131
Pain89
Neurology1
Merck KGaA
0 catalysts
Marketed
birch triterpenes
Filsuvez (birch triterpenes)
Epidermolysis Bullosa
Chiesi USA Inc
0 catalysts
Phase 2
birelentinib
Refractory Chronic Lymphocytic Leukemia (CLL)
Dizal Pharmaceutical Co Ltd
0 catalysts
Phase 2
bisantrene
Zantrene (bisantrene)
Refractory Acute Myeloid Leukemia
Alpha-ketoglutarate-dependent dioxygenase FTO
Racura Oncology Ltd
0 catalysts
Marketed
bismuth subsalicylate + metronidazole + tetracycline hydrochloride
Bismuth Subsalicylate + Metronidazole + Tetracycline Hydrochloride (bismuth subsalicylate + metronidazole + tetracycline hydrochloride)
Duodenal Ulcer
Ailex Pharmaceuticals LLC
0 catalysts
Preclinical
bisprezatide copper
Unspecified
PharmaTher Holdings Ltd
0 catalysts
Phase 2
bitopertin
Anemia
Sodium- and chloride-dependent glycine transporter 1
$IRONDisc Medicine, Inc.
0 catalysts
Marketed
bivalirudin
Bivalirudin (bivalirudin)
Heparin-Induced Thrombocytopenia
Avenacy Inc
0 catalysts
Phase 2
bivamelagon
bivamelagon [INN]
Obesity
$RYTMRHYTHM PHARMACEUTICALS, INC.
0 catalysts
Phase 2
bizaxofusp
bizaxofusp [INN]
Recurrent Glioblastoma Multiforme (GBM)
$MDNAFMedicenna Therapeutics Corp.
0 catalysts
Marketed
black widow spider [Latrodectus mactans] antivenom [equine]
Antivenin (Lacrodectus mactans)
Poisoning
$MRKMerck & Co., Inc.
0 catalysts
Phase 3
blarcamesine hydrochloride
Fragile X Syndrome
$AVXLANAVEX LIFE SCIENCES CORP.
0 catalysts
Marketed
bleomycin sulfate
Bleomycin Sulfate (bleomycin sulfate)
Cervical Cancer
Northstar Rx LLC
0 catalysts
Phase 2
bleximenib besylate
Refractory Acute Myeloid Leukemia
$JNJJOHNSON & JOHNSON
0 catalysts
Phase 2
bocunebart
bocunebart [INN]
Migraine
H. Lundbeck AS
0 catalysts
Phase 3
bomedemstat tosylate
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
$MRKMerck & Co., Inc.
0 catalysts
Phase 2
bosakitug
bosakitug [INN]
Atopic Dermatitis (Atopic Eczema)
$ACRSAclaris Therapeutics, Inc.
0 catalysts
Marketed
bosutinib
Bosutinib (bosutinib)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Alembic Pharmaceuticals Inc
0 catalysts
Phase 3
botaretigene sparoparvovec
Retinitis Pigmentosa (Retinitis)
Johnson & Johnson Innovative Medicine
0 catalysts
Phase 2
botensilimab
Metastatic Colorectal Cancer
$AGENAGENUS INC
0 catalysts
Phase 2
botulinum vaccine [serogroups A, A1, B and B1]
Botulism
U.S. Army Medical Research Institute of Infectious Diseases
0 catalysts
Marketed
botulism [Clostridium botulinum] [serotype A, B, C, D, E, F, G] (heptavalent) antitoxin [equine]
BAT
Botulism
$EBSEmergent BioSolutions Inc.
0 catalysts
Marketed
botulism immune globulin (human)
Babybig (botulism immune globulin (human))
Botulism
FFF Enterprises Inc
0 catalysts
Phase 3
brelovitug
brelovitug [INN]
Hepatitis D
$MIRMMirum Pharmaceuticals, Inc.
0 catalysts
Marketed
bremelanotide acetate
Vyleesi (bremelanotide acetate)
Obesity
Melanocortin receptor 4
$PTNTPALATIN TECHNOLOGIES INC
0 catalysts
Marketed
brensocatib
Brinsupri (brensocatib)
Bronchiectasis
$INSMINSMED Inc
0 catalysts
Marketed
brexanolone
Brlizio (brexanolone)
Post Partum Depression (Maternal Depression / Postnatal Depression)
GABA-A receptor; anion channel
$LPCNLipocine Inc.
0 catalysts
Phase 2
brexucabtagene autoleucel
Tecartus (brexucabtagene autoleucel)
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
B-lymphocyte antigen CD19
$GILDGILEAD SCIENCES, INC.
0 catalysts